bluebird bio Secures $60 Million in Oversubscribed Financing

Proceeds will Further Strengthen bluebird’s Proprietary Gene Therapy Platform and Advance Multiple Clinical Programs in Severe Genetic Disorders, Including a Global ALD Phase 2/3 Study